Provided by Tiger Trade Technology Pte. Ltd.

Carpenter Technology

443.19
-5.0600-1.13%
Post-market: 443.190.00000.00%16:15 EDT
Volume:403.15K
Turnover:179.88M
Market Cap:21.96B
PE:42.13
High:457.43
Open:455.30
Low:441.88
Close:448.25
52wk High:625.99
52wk Low:228.00
Shares:49.56M
Float Shares:48.15M
Volume Ratio:0.87
T/O Rate:0.84%
Dividend:0.80
Dividend Rate:0.18%
EPS(TTM):10.52
EPS(LYR):10.52
ROE:25.75%
ROA:11.87%
PB:9.86
PE(LYR):42.13

Loading ...

CRS Initiative Launches, Tax Authorities to Verify Overseas Income for Three Consecutive Years

Deep News
·
Apr 23

Earning Preview: Carpenter Technology Q3 revenue expected to increase by 9.37%, and institutional views are bullish

Earnings Agent
·
Apr 23

Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia

GlobeNewswire
·
Apr 21

Carpenter Technology price target raised to $465 from $394 at JPMorgan

TIPRANKS
·
Apr 20

U.S. RESEARCH ROUNDUP-Carpenter Technology, IBM, Ulta Beauty

Reuters
·
Apr 20

KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma

GlobeNewswire
·
Apr 20

How Dividend Reaffirmation And Institutional Demand At Carpenter Technology (CRS) Has Changed Its Investment Story

Simply Wall St.
·
Apr 19

Antengene Presents Three Novel Programs at AACR 2026, Highlighting Next-Generation ADC and AnTenGager® TCEs

prnewswire
·
Apr 18

Carpenter Technology Announces Leadership Transition and Board Expansion

TIPRANKS
·
Apr 18

Carpenter names Brian Malloy CEO, Tony Thene to become executive chairman

Reuters
·
Apr 18

Carpenter Technology Keeps Quarterly Dividend at $0.20 a Share, Payable June 4 to Holders of Record as of April 28

MT Newswires Live
·
Apr 17

Press Release: Carpenter Technology Declares Quarterly Cash Dividend

Dow Jones
·
Apr 17

Poolbeg wins UK trial clearance as POLB 001 tipped for multi‑billion‑dollar CRS market

TIPRANKS
·
Apr 15

Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform

GlobeNewswire
·
Apr 14

Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL

GlobeNewswire
·
Apr 13

Susquehanna Remains a Buy on Carpenter Technology (CRS)

TIPRANKS
·
Apr 11

Southern Copper Corp Stock (SCCO) Moved Up by 3.81% on Apr 10: Drivers Behind the Movement

TradingKey
·
Apr 10

Carpenter Tech Is Maintained at Overweight by Keybanc

Dow Jones
·
Apr 09

U.S. RESEARCH ROUNDUP-3M, CME Group, TransDigm Group

Reuters
·
Apr 08

Carpenter Technology Corp : TD Cowen Raises Target Price to $430 From $380

THOMSON REUTERS
·
Apr 08